Literature DB >> 24555412

RNA metabolism in ALS: when normal processes become pathological.

Cristian A Droppelmann1, Danae Campos-Melo, Muhammad Ishtiaq, Kathryn Volkening, Michael J Strong.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by the death of motor neurons. While the exact molecular and cellular basis for motor neuron death is not yet fully understood, the current conceptualization is that multiple aberrant biological processes contribute. Among these, one of the most compelling is based on alterations of RNA metabolism. In this review, we examine how the normal process of cellular response to stress leading to RNA stress granule formation might become pathological, resulting in the formation of stable protein aggregates. We discuss the emerging roles of post-translational modifications of RNA binding proteins in the genesis of these aggregates. We also review the contemporary literature regarding the potential role for more widespread alterations in RNA metabolism in ALS, including alterations in miRNA biogenesis, spliceosome integrity and RNA editing. A hypothesis is presented in which aberrant RNA processing, modulated through pathological stress granule formation as a reflection of either mutations within intrinsically disordered or prion-like domains of critical RNA binding proteins, or the post-translational modification of RNA binding proteins, contributes directly to motor neuron death.

Entities:  

Keywords:  ALS; RNA metabolism; neuronal cytoplasmic inclusions; post-translational modifications; stress granule

Mesh:

Substances:

Year:  2014        PMID: 24555412     DOI: 10.3109/21678421.2014.881377

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  24 in total

1.  Characterization of the Mitochondrial Aerobic Metabolism in the Pre- and Perisynaptic Districts of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Silvia Ravera; Tiziana Bonifacino; Martina Bartolucci; Marco Milanese; Elena Gallia; Francesca Provenzano; Katia Cortese; Isabella Panfoli; Giambattista Bonanno
Journal:  Mol Neurobiol       Date:  2018-04-14       Impact factor: 5.590

Review 2.  Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era.

Authors:  Ximena Paez-Colasante; Claudia Figueroa-Romero; Stacey A Sakowski; Stephen A Goutman; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

Review 3.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 4.  Transcriptomics and Metabolomics in Amyotrophic Lateral Sclerosis.

Authors:  Marios G Krokidis
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Proteomic Analysis of Dynein-Interacting Proteins in Amyotrophic Lateral Sclerosis Synaptosomes Reveals Alterations in the RNA-Binding Protein Staufen1.

Authors:  Noga Gershoni-Emek; Arnon Mazza; Michael Chein; Tal Gradus-Pery; Xin Xiang; Ka Wan Li; Roded Sharan; Eran Perlson
Journal:  Mol Cell Proteomics       Date:  2015-11-23       Impact factor: 5.911

6.  Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS.

Authors:  Anna Emde; Chen Eitan; Lee-Loung Liou; Ryan T Libby; Natali Rivkin; Iddo Magen; Irit Reichenstein; Hagar Oppenheim; Raya Eilam; Aurelio Silvestroni; Betty Alajajian; Iddo Z Ben-Dov; Julianne Aebischer; Alon Savidor; Yishai Levin; Robert Sons; Scott M Hammond; John M Ravits; Thomas Möller; Eran Hornstein
Journal:  EMBO J       Date:  2015-09-01       Impact factor: 11.598

7.  Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients.

Authors:  Michele Benigni; Claudia Ricci; Ashley R Jones; Fabio Giannini; Ammar Al-Chalabi; Stefania Battistini
Journal:  Neuromolecular Med       Date:  2016-04-27       Impact factor: 3.843

8.  Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis.

Authors:  Michail S Kukharsky; Annamaria Quintiero; Taisei Matsumoto; Koji Matsukawa; Haiyan An; Tadafumi Hashimoto; Takeshi Iwatsubo; Vladimir L Buchman; Tatyana A Shelkovnikova
Journal:  Mol Neurodegener       Date:  2015-04-10       Impact factor: 14.195

Review 9.  The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases.

Authors:  Cristian A Droppelmann; Danae Campos-Melo; Kathryn Volkening; Michael J Strong
Journal:  Front Cell Neurosci       Date:  2014-09-10       Impact factor: 5.505

Review 10.  ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease.

Authors:  Elizabeth B Moloney; Fred de Winter; Joost Verhaagen
Journal:  Front Neurosci       Date:  2014-08-14       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.